Evaluation of Cardiac Troponin Levels in Individuals Aged 12 to 30 Years Following mRNA-1273 Vaccination: Results From a Randomized Placebo-Controlled Trial
Susan Pfeiffer·Spyros Chalkias·Frances Priddy·Bethany Biron Girard·Margaret Rhee·Walter Straus·Scott P. Striplin·Xiaowei Wang·Verónica Urdaneta
Abstract Background Myocarditis is a very rare event following COVID-19 vaccination, with highest risk observed in males aged 12–24 years. Cardiac troponin I (cTnI) is a cardiac-specific biomarker of myocardial injury but is not etiologically specific and may be elevated in the absence of cardiac pathology, including after vigorous physical activity. This study assessed cTnI levels following administration of mRNA-1273.712 vaccine versus placebo in participants aged 12–30 years. Methods In this